Intellia Therapeutics Inc (NTLA NASDAQ) stock market data APIs
$11.5493
0.23(2%)
as of September 15, 2025
Try our APIs with
free plan!
Intellia Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev. Close
11.5493
Open
11.7814
High
12.024
Low
11.4744
52 wk Range
5.9-23.76
Market Cap
1 242 M
Shares Outstanding
107 M
Revenue
52 857 K
EPS
-0.98
Beta
2.284
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Intellia Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Intellia Therapeutics Inc data using free add-ons & libraries
Get Intellia Therapeutics Inc Fundamental Data
Intellia Therapeutics Inc Fundamental data includes:
- Net Revenue: 52 857 K
- EBITDA: -501 873 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -1.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intellia Therapeutics Inc News
New
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
Key Points Cathie Wood favors buying innovators when their stock prices are down and holding on for the long term. Wood’s strategy has helped her flagship fund soar 80% over the past year. 10 stock...
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?
A month has gone by since the last earnings report for Xenon Pharmaceuticals (XENE). Shares have added about 4.2% in that time frame, outperforming the S&P 500. But investors have to be wondering, wi...
Cathie Wood’s Ark Invest buys the dip in Figma as stock sinks ~20%
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s investment manager Ark Invest has bought over 100K shares of...
Tesla's India Dream Hits a Wall: Just 600 Orders, While BYD Doubles Down
This article first appeared on GuruFocus. Tesla (NASDAQ:TSLA) may have entered India with brand swagger and long-term ambition, but the initial numbers tell a more muted story. Since launching sales ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
